3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
5
Leukemia, Hairy Cell
3
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Carcinoma in Situ
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Vomiting
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Nausea and Vomiting
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
NSCLC
1
Myelodysplastic Syndromes
1
Mastocytosis, Systemic
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Diphenhydramine
×
1 year
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts